Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer

Fig. 6

Treatment strategies for non-responders. The distribution in responses of 30 patients were sketched for each treatment strategy using 30 sets of good fits of calibrated parameters for non-responders (solid line represents median while dotted lines enclose 90% of the predictions). A sample set of parameter values used in the plots is listed in Table 2. a. Effects of increased interleukin-12 (IL-12) dose from 1 time (1X, control) to 3, 5, 10 times (3X, 5X, 10X, respectively). b. Effects of moderately increased OXP dose from 1 time (1X, control) to 2, 4, 6 times (2X, 4X, 6X, respectively). c. Effects of aggressively increased OXP dose from 1 time (1X, control) to 10, 100, 200 times (10X, 100X, 200X, respectively). d. Effects of increased number of treatment cycles from 3 cycles to 4, 5, and 6 cycles

Back to article page